

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office, Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/932,300	08/17/2001	Eric Garver	9855-3U2	5387
570 7	590 06/11/2003			·
AKIN GUMP STRAUSS HAUER & FELD L.L.P. ONE COMMERCE SQUARE 2005 MARKET STREET, SUITE 2200			EXAMINER	
			SCHMIDT, MARY M	
PHILADELPH	IIA, PA 19103-7013	·	ART UNIT	PAPER NUMBER
			1635	9
			DATE MAILED: 06/11/2003	<u>-</u>

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summany	09/932,300	GARVER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mary M. Schmidt	1635				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on	<u> </u>					
2a)☐ This action is FINAL . 2b)☐ Th	is action is non-final.	•				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>1-33 and 44</u> is/are pending in the app	olication.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.	•	•				
7) Claim(s) is/are objected to.						
8) Claim(s) 1-33 and 44 are subject to restriction and/or election requirement. Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are; a)☐ accep	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	e drawing(s) be held in abey	yance. See 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
 1. Certified copies of the priority documents 	s have been received.					
2. Certified copies of the priority documents	s have been received in A	Application No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)				
J.S. Patent and Trademark Office	·					

Application/Control Number: 09/932,300

Art Unit: 1635

DETAILED ACTION

Page 2

Election/Restriction

1. Pursuant to 35 U.S.C. 121 and 37 C.F.R. 1.141, (1) the antisense sequences listed in claims 13-15 are subject to restriction, and (2) the target gene sequences listed in claims 2-5 and 33 are subject to restriction. As per M.P.E.P. 2434, "the Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of such nucleotide sequences to be claimed in a single application. Under this policy, in most cases, up to 10 independent and distinct nucleotide sequences will be examined in a single application without restriction. Those sequences which are patentably indistinct from the sequences selected by the applicant will also be examined."

- (1) Claim 13 specifically claims SEQ ID NOS: 98, 107, 109, and 111. Claim 14 specifically claims SEQ ID NO:98. Claim 15 specifically claims SEQ ID NO:111. Each of these oligonucleotide sequences is considered to be structurally independent and distinct even though they each target the same gene, because each of these oligonucleotides has a unique nucleotide sequence and each targets a different and specific region of the gene.
- (2) Claim 2 states that the aldehyde dehydrogenase gene is ALDH2. Claim 4 states that the ALDH2 is the ALDH2-1 allele. Claim 5 states that the ALDH2, human sequence, is either SEQ ID NO:108 or 110. Claim 33 is drawn to expression of an ALDH2-2 allele. Each ALDH2 is considered to be structurally independent and distinct since they are different gene sequences

Art Unit: 1635

and require a different search. Thus applicant is required to choose either the ALDH2-1 or ALDH2-2 allele, and if the ALDH2-1 is chosen, either SEQ ID NO:108 or 110 must be elected for consideration on the merits.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Art Unit: 1635

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mary M. Schmidt*, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *John LeGuyader*, may be reached at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed *Katrina Turner*, whose telephone number is (703) 305-3413.

M. M. Schmidt June 7, 2003

JOHN L. LEGUYADER UPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600